The UK government has launched a new Life Sciences Sector Plan, a ten-year strategy designed to boost the country’s position as a global leader in life sciences. Announced on Wednesday 16 July, the plan is a core part of the government’s wider Industrial Strategy and its Plan for Change, combining economic growth ambitions with sweeping NHS reform.
The life sciences sector already contributes around £100 billion to the UK economy and employs over 300,000 people across the country. This new plan is intended to build on that strength by converting scientific innovation into tangible health and economic outcomes. At its centre is a commitment to move from high-level ambition to practical delivery, with a focus on investment, simplification of regulation, and a deeper integration of technology across the NHS.
£2 billion in funding
Over the lifetime of the Spending Review, more than £2 billion in government funding will support the plan, in addition to investments from UK Research and Innovation (UKRI) and the National Institute for Health and Care Research (NIHR). A further £520 million will go towards the Life Sciences Innovative Manufacturing Fund to stimulate domestic production, and up to £600 million has been allocated to develop the world’s most advanced health data system.
The government’s plan is structured around three strategic pillars: enabling world-class research and development, making the UK a globally attractive place for investment, and driving innovation within the NHS. These goals are underpinned by six immediate actions.
Unlocking NHS health data
First, a large-scale investment will enable the unlocking of NHS health data to accelerate the discovery of treatments and improve diagnoses. The Health Data Research Service will play a key role in this effort, offering researchers and clinicians access to integrated, high-quality data.
Second, reforms to clinical trial regulation will reduce bureaucracy, aiming to shorten trial setup times and speed up patient access to new therapies. This includes changes that will make it easier for patients to participate in trials and for researchers to scale them.
Third, the government will increase support for British manufacturing in life sciences, helping to create high-skilled jobs and improve domestic resilience in the supply of medical technologies and treatments.
Fourth, regulation is being streamlined to help doctors access safe and effective treatments more quickly. Additional resources for the Medicines and Healthcare products Regulatory Agency (MHRA) will accelerate approvals.
Fifth, the introduction of an NHS ‘innovator passport’ will make it easier for proven technologies, such as AI diagnostic tools and wearable devices, to be adopted quickly across the healthcare system.
Lastly, new measures will support the growth of UK-based life sciences firms, encouraging investment and ensuring that innovation and talent remain within the country. At least one major industry partnership is expected to be secured each year as part of this drive.
Adding economic and social value
This approach reflects the government’s belief in the sector’s ability to create both economic and social value. Better health outcomes directly support workforce productivity, particularly as long-term illness continues to be a drag on participation. At the same time, the UK is attracting increasing levels of international capital, with 2023 seeing the country raise the third-highest amount of life sciences equity finance globally, behind only the United States and China.
The plan also comes as the government steps up efforts to simplify the regulatory environment and reduce costs. Recent investments in the MHRA and initiatives to align processes between the MHRA and the National Institute for Health and Care Excellence (NICE) are aimed at accelerating MedTech approvals and improving efficiency.
AI plays a crucial role
Artificial intelligence also plays a central role in the strategy, with its potential recognised across diagnostics, treatment and research. According to McKinsey, AI could generate between $60 billion and $110 billion annually for the pharmaceutical and medical-product industries worldwide. The UK’s emphasis on AI-enabled tools for clinical decision-making and disease prevention highlights a growing commitment to technological transformation in healthcare.
Crucially, the Sector Plan was developed through consultation with more than 250 organisations, including NHS leaders, researchers, and industry experts. Its emphasis on execution is matched by the creation of clear responsibilities and defined goals for each action.
Speaking at the plan’s launch, Science and Technology Secretary Peter Kyle said: “The life sciences sector is one of the crown jewels of the UK economy. It sits at the heart of both our Plan for Change, and our Modern Industrial strategy, as a unique catalyst for both economic prosperity, and better health outcomes for people across the UK.”
Health Secretary Wes Streeting added: “This Life Sciences Sector Plan represents a pivotal moment in our mission to rebuild the NHS and shift our healthcare system from one that treats illness to one that prevents it.”
The unveiling coincided with the fourth Made in the UK, Sold to the World Roadshow, designed to support SME exports in the life sciences sector. The initiative highlights the government’s commitment to sectors with the highest growth potential, with life sciences recognised as one of eight key priority industries.
With implementation already underway – including investment in the Health Data Research Service and support for projects such as Genomics England and Our Future Health – the government’s message is clear. The Life Sciences Sector Plan is not just a proposal. It is a detailed, funded, and collaborative framework designed to make the UK a global leader in scientific innovation and preventative healthcare.
Life Sciences Week
With Life Sciences positioning itself as a key focus of the government and private sector investment, Life Sciences Week provides an opportunity for all those involved in the industry to connect, network and share ideas.
